OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2018.8424 OL-0-0-8424 Articles Elevated peripheral blood B lymphocytes and CD3+CD4−CD8− T lymphocytes in patients with non-small cell lung cancer: A preliminary study on peripheral immune profile LiangHailong 1 ChuXiangyang 1 ZhaoJing 2 XingGuosheng 2 SiYingjian 3 Department of Thoracic Surgery, General Hospital of People's Liberation Army, Beijing 100853, P.R. China Department of Thoracic Surgery, General Hospital of Beijing Command, Beijing 100700, P.R. China Department of Pediatrics, General Hospital of Beijing Command, Beijing 100700, P.R. China Correspondence to: Dr Xiangyang Chu, Department of Thoracic Surgery, General Hospital of People's Liberation Army, 28 Fu Xing Road, Hai Dian, Beijing 100853, P.R. China, E-mail: drchu0521@163.com 06 2018 04 04 2018 15 6 8387 8395 15042016 20072017 Copyright: © Liang et al. 2018 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

It has been established that the tumor microenvironment (TME) has a crucial role in enabling tumors to evade from host immune responses. Previous studies demonstrated that tumor cells are not only able to reshape immune milieu at the tumor site, but also exert systemic effects, which has been demonstrated to be important for metastasis. At present, how the peripheral immune environment change in the tumor-bearing host is unclear. The present study identified a number of changes in the proportions of lymphocyte subpopulations and the levels of cytokines in patients with NSCLC, which may provide a preliminary profile of the immune environment in the peripheral blood of patients harboring a tumor. These findings expand on the present knowledge on how tumors can alter the immune system to benefit its growth and metastasis, which may provide a potential novel strategy for immunotherapy.

 non-small cell lung cancer peripheral immune environment metastasis tumor immune system Introduction

Malignant tumor is able to elicit host immune response (1–4). However, according to the cancer immunoediting theory, subpopulations of genetically heterogeneous neoplastic cells evolve to escape immune surveillance and thrive (5). During recent decades, numerous experimental and clinical studies have demonstrated that tumor cells surviving from immune surveillance acquire various (6) capacities to change constitution and/or function of immune and stromal cells at the tumor site, creating topical immunosuppressive milieu, thus the concept of tumor microenvironment (TME) was proposed (7), which could partly explain why and how tumor cells avoid antitumor immune responses. The specific mechanisms involved in TME are highly complicated, including tumor cell exploiting co-inhibitory signaling molecules through interaction with immune cells, secretion of immunosuppressive cytokines, recruitment of immune regulatory cells [regulatory T lymphocyte (Treg) and myeloid-derived suppressor cell (MDSC)], inducing cancer-related fibroblast and tumor-associated macrophage, and other unidentified pathways (6,8–10). Notably, a number of these mechanisms are important self-protective measures from tissue damage caused by excessive immune reaction (11,12). Based on these findings, a number of monoclonal antibody agents were developed which benefit many patients with malignant tumors (13–15). To date, the critical role of TME in altering the biological behaviors of tumors have been established, and it is proposed that genetic alterations in neoplastic cells as well as the host immune system affect tumorigenesis and progression (16).

Moreover, experimental evidence suggests that primary tumor lesions are able to exert systemic effects by various means. For example, a number of studies demonstrate that the systemic effects of the tumor are able to form so-called pre-metastatic niches in distant tissues or organs, and also facilitate its own progression (17–22). By contrast, some studies indicate that the systemic effects of the tumor are able to inhibit metastasis (23,24). In spite of these inconsistent findings, it has been demonstrated that the tumor is able to exhibit systemic effects. Therefore, it is hypothesized since tumor cells are able to reshape immune and stromal cell profile at the tumor site, the systemic effects of the tumor may adapt peripheral immune components to create a pro-tumor peripheral immune environment. Nevertheless, at present, there is a lack of direct evidence for peripheral immune profile in tumor patients.

The present authors are particularly interested in tumor metastasis, which is also the most common type of relapse for the majority of malignancies following complete resection and adjuvant therapies, particularly for lung cancer, which has one of the highest cancer-associated mortalities and incidence among malignant tumors according to recent statistics (25). Numerous patients with small primary malignant lesions develop metastasis, which suggests that metastasis is a relatively unique process inproportionate with the topical progression of the tumor (26).

At present, there is limited information regarding why and how tumor cells can be safely transported through the blood or lymphatic vessel to another organ or lymph node without being captured and killed by circulating immune components. Another question is how latent micrometastasis develop to be clinically detectable. Theoretically, if the peripheral immune system were robust, it would be highly probable for metastatic tumor cells in circulation to be eliminated. Therefore, the present authors hypothesize that the peripheral immune environment may be adapted in a way so the metastatic cells can evade from the immune response.

In the present study, a preliminary study was performed to characterize the profile of the peripheral circulating immune system in patients with non-small cell lung cancer (NSCLC) and healthy controls by assaying the proportion of lymphocyte subpopulations and the levels of a number of tumor-associated cytokines. Furthermore, comparisons were also performed between NSCLC patients with and without metastasis.

 Materials and methods

The present study was conducted following Human Experimentation Review and approved by Research Ethics Committee of the General Hospital of People's Liberation Army and the General Hospital of Beijing Command. Informed consent was obtained from all patients enrolled in the present study, and information from the patients was protected. From April 2015 to December 2015, 48 eligible patients with NSCLC, who were admitted to either the General Hospital of Beijing Command (Beijing, China) or the General Hospital of People's Liberation Army (Beijing, China), were included in the present study. Patient age ranged from 42–72 years, with the mean age of 56. The inclusion criteria were as follows: i) Having a clinical diagnosis of lung cancer; ii) being newly diagnosed without receiving any antitumor therapy; iii) without acute or chronic inflammatory disease during study; iv) without suffering from immunodeficiency condition; v) without suffering from immune-related disease; vi) without a history of long-term drug therapy that may affect immunity. The exclusion criteria were as follows: i) Pathological diagnosis of benign disease or small cell lung cancer (SCLC); ii) without pathological diagnosis; iii) incomplete examinations and iv) the presence of other concomitant malignancy. A total of 21 patients admitted to General Hospital of Beijing Command were also included as the control group: Two patients were pathologically diagnosed as lung hamartoma, one patient was pathologically diagnosed as costal fibrous dysplasia, and 18 patients were diagnosed as congenital chest wall deformity. The inclusion criteria for the control group were as follows: i) Without any type of malignant tumor; ii) without acute or chronic inflammatory disease during study; iii) without suffering from immunodeficiency disorders; iv) without suffering from immune-related disease and v) without a history of long-term drug therapy that may affect immunity. All participants were divided into two groups: NSCLC group and control group. Additionally, the NSCLC group was further divided into two subgroups: Subgroup I (NSCLC at stage I; n=17) and subgroup II (NSCLC with metastasis; n=31). In subgroup I, 16 patients were at pathological stage I, and 1 patient was at clinical stage I. In subgroup II, lymph node metastasis was pathologically confirmed, and distant metastasis was confirmed with imaging.

<sec> <title>Peripheral blood and serum sample

Peripheral venous blood were obtained from patients in the morning and stored separately in heparin-coated and non-coagulated tubes. The blood samples were transferred immediately to the laboratory. Serum was aliquoted by centrifugation (200 × g for 10 min) at room temperature, then stored at −80°C for subsequent assay to detect the level of cytokines.

 Flow cytometric assay of lymphocyte subpopulations

The reagents used for immunostaining were as follows: Fluorescein isothiocyanate (FITC) or phycoerythrin cyanin (PC)7-conjugated anti-cluster of differentiation (CD)3 (20 µl; catalog no. 6607100) PC5-conjugated anti-CD4 (10 µl; catalog no. H07752), FITC-conjugated anti-CD8 (20 µl; catalog no. H07756), phycoerythrin (PE)-conjugated anti-CD25 (20 µl; catalog no. H07774), PC7-conjugated anti-CD19 (10 µl; catalog no. IM3628), PE-conjugated anti-CD56 (20 µl; catalog no. H07788) and PE-conjugated anti-CD16 (20 µl; catalog no. H07766) (all from Beckman Coulter, Inc., Brea, CA, USA).

 Cell staining

Blood samples were stained according to the manufacturer's instructions, and the following panels were designed: i) CD8-FITC/CD25-PE/CD45-ECD/CD4-PC5/CD3-PC7 and ii) CD3-FITC/CD16+56-PE/CD45-ECD/CD14-PC5/CD19-PC7.

 Quantification by flow cytometry

Following staining, the blood samples were assayed using a 5-colored uni-laser flow cytometer (FC500; Beckman Coulter, Inc.). Data analysis was undertaken using the CXP software (Beckman Coulter, Inc., Brea, CA, USA. The combinations of antibodies used for analysis are follows: CD3+ for T lymphocytes, CD19+ for B lymphocytes, CD3+CD4-CD8- for double-negative T lymphocytes (DN T cells), CD3+CD4+CD25+ for activated T lymphocytes, CD3+CD4+CD25 high roughly for Treg, CD3+CD16+CD56+ for natural killer T cells and CD3-CD16+CD56+ for natural killer cells.

 Flow cytometric assay of serum cytokines

Serum cytokine levels [including interferon (IFN)-γ, tumor necrosis factor (TNF)-α, transcription growth factor (TGF)-β, interleukin (IL)-2, IL-4, IL-6, IL-10 and IL-17A] were assayed by using the commercially available Aimplex human Th1/Th2/Th17plex assay kit and the human TGF-β assay kit, from AimPlex Biosciences, (Pomona, CA, USA) and Beijing Quantobio Biotechnology Co., Ltd. (Beijing, Chin), respectively, following the manufacturer's instructions. Quantitation measurements were performed by a 4-colored uni-laser flow cytometer (FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA). FCAP Array software (version 3.0) was used to process data. Standard curves for each type of cytokine were generated with manufacturer-supplied reference analytes.

 Statistical analysis

The data are presented as the mean or mean ± standard deviation. To compare the proportion of lymphocytes and subpopulations between groups, Student's t-test or Wilcoxon rank-sum test were used. Similarly, Student-test or Wilcoxon rank-sum test was used to compare concentrations of cytokines between groups. P<0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using the SPSS software (version 13; SPSS, Inc., Chicago, IL, USA).

 Results <sec> <title>General characteristics of the participants

There were 48 eligible NSCLC patients participating the present study. Among them, 30 cases were male, 18 cases were female. A total of 29 cases were diagnosed with adenocarcinoma, 14 cases with squamous cell carcinoma, 3 cases were adenosquamous carcinoma and 2 cases with large cell carcinoma (Table I).

Distribution of lymphocyte subpopulations as determined by flow cytometric analysis (Fig. 1A-D). Lymphocyte subsets between the NSCLC group and the control group were compared (Table II). The results indicated that the percentage of lymphocytes in the NSCLC group was significantly lower compared with the control group (P=0.008; Fig. 2). Additionally, the proportion of B cells (CD19+) among lymphocytes in the NSCLC group was significantly lower compared with the control group (P<0.0001; Fig. 3 and Table II). The proportion of DN T cells (CD3+CD4-CD8-) among lymphocytes in the NSCLC group was significantly lower compared with the control group (P=0.001; Fig. 4 and Table II). However, there were no significant differences in the proportion of other subpopulations assayed (Table II). The ratio of CD4+/CD8+ cells was not significantly different between the NSCLC group and the control group (Table II).

Subsequently, comparisons between subgroups I and II were performed (Table III). The percentage of lymphocytes in subgroup I was significantly higher compared with subgroup II (P<0.0001; Fig. 5 and Table III). However, there were no significant differences in the proportion of other assayed subpopulations between subgroups I and II. There were also no significant differences between the two groups in the proportions of CD3+CD4+CD25+, CD3+CD4+CD25high and CD3+CD4+ cells (Table III).

 Levels of cytokines

In the present study, the levels of eight types of cytokines, including IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-α, TGF-β and IFN-γ were analyzed. Comparisons were performed for each of the eight cytokines between the NSCLC group and the control group. The results indicated that the levels of IL-6 in the NSCLC group were significantly higher compared with the control group (0.008) (Table IV). However, there were no significant differences for other cytokines (Table IV). Subsequently, comparisons were performed in the levels of cytokines between subgroups I and II, and no significant differences were identified (Table IV).

 Discussion

Malignant tumor remains one of the biggest threats to human health. According to statistics, the total number of cancer-associated mortalities worldwide in was 8.2 million, and the number of newly diagnosed cases was 14.1 million (25). Although intensive research has been conducted to unravel tumorigenesis and to identify novel therapeutic approaches and as a result enormous progress has been made in knowledge and clinical management, there remains to be questions regarding the underlying mechanisms of tumor.

Molecular and biological studies revealed that neoplastic cells are genetically unstable and heterogeneous, which account for complexity and diversity of tumorigenesis and its biological behaviors. Host immune response targeting malignant tumor in patients and animal models have long been observed (1–3,27). As conventional therapeutic modalities are mostly concerned with prolonging the survival time of patients with marked toxic side effects, various types of immunotherapy have been attempted for decades (28). During the recent decade, the breakthrough finding of TME made tumor immunology another focus for investigation in tumor biology.

It is now clear that tumor cells have evolved to acquire various capacities to alter the topical milieu of tumor tissues, and to facilitate proliferation and invasion (29). The complicated mechanisms remain to be completely elucidated, and mechanisms that have been established includes exploitation of co-inhibitory checkpoint molecules through interaction between tumor cells and immune effector cells, recruitment of immune suppressive cells (Tregs and MDSCs), secretion of inhibitory cytokines and other agents, and reshaping the function of stromal and immune cells (6,8–10,30). These findings provide new strategy and targets for immunotherapy, and newly developed monoclonal agents based on these findings have achieved good clinical effects (13,14).

Since TME has a critical role in the biological behavior of tumor, it has been proposed that the involvement of the immune system is equally important in tumor development. Recently, evidence suggested that tumor cells were not only able to manipulate and reform local environment, but also exert systemic influence through tumor-derived cytokines and microvesicles. It was demonstrated that the systemic effects of the tumor could compromise distant tissues and organs so as to facilitate metastasis, and promote tumor growth (16). Nevertheless, there were also a number of studies (31) with inconsistent results (24). These seemingly contradictory findings suggest the complexity of the systemic effects of tumors.

Theoretically since tumors are able to exert systemic effects, it is highly likely that they may adapt to the peripheral environment to facilitate progression and metastasis (32). Increasing evidence suggest that tumor is a systemic disease in that topical alteration within tumor tissue is closely associated with its systemic effect, for example the recruitment of Tregs into tumor site is accompanied by increased levels of Tregs in the peripheral blood (33,34).

In the present study, the changes in the proportions of peripheral lymphocytes and subpopulations were analyzed. The findings indicated that the percentage of lymphocytes in the NSCLC group was significantly lower compared with the control group (P=0.008). This is in accordance with results in other types of malignant tumor (35,36).

To date, the reason or specific mechanisms for lymphopenia in malignant tumor is unclear. Ray-Coquard et al (37) proposed that a decreased lymphocyte count might reflect immunosuppressive condition in the tumor-bearing host, which suggest that the host tends to have an inadequate immunological reaction. A decreased lymphocyte count might also be a consequence of lympholysis caused by cytokines produced by tumor cells in the case of lymphoma (37).

The present study hypothesized that decreased lymphocyte count in tumor-bearing host is caused by tumor lesion, which is supported by evidence that elimination of tumor lesion by tumor antigen vaccination treatment is able to normalize decreased lymphocyte frequency (37). The results of the present study indicated that the percentage of lymphocytes in NSCLC with metastasis is significantly lower compared with the percentage in early stage NSCLC, which also support the hypothesis that decreased lymphocyte is associated with tumor progression. In addition, since tumor with metastasis is indicative of poor prognosis, the findings of the present study support that lymphopenia is an independent prognostic factor for overall and progression-free survival in cancer (37). However, the specific underlying mechanisms of how tumor affects the proportion of peripheral lymphocytes require further studies.

In the present study, it was observed that the proportion of CD3+CD4-CD8-cells, a poorly known subpopulation in the peripheral blood, was significantly lower compared with the control group (P=0.001), which has not been reported in any types of tumor previously. CD3+CD4-CD8-lymphocytes are also known as DN T cell with αβT-cell receptor (TCR) or γδTCR. The CD3+CD4-CD8-subpopulation is very small in number and represents 1–3% of peripheral mononuclear cells. CD3+CD4-CD8-cells are mainly distributed in the peripheral blood and lymph nodes (38,39). A previous study demonstrated that this novel subset of T cell might have a role in autoimmune disease, transplantation, viral infection and malignant tumor by exerting different functions (40). DN T cells are able to suppress CD4+ and CD8+ T cell-mediated response by eliminating effector T cells in murine models via the combination of Fas/Fas ligand or perforin/granzyme secretion, or suppressing the proliferation of activated T cells in humans via cell-cell interactions (41). Due to immunosuppressive properties of DN T cells, DN T cell has been proposed as a novel therapeutic target for autoimmune disease and transplantation. Studies have demonstrated that DN T cells are able to enhance the survival of organ allografts and xenografts (42). In human infections caused by the human immunodeficiency virus and Simian immunodeficiency virus, DN T cells are able to exert T helper cell-like functions in compensation for very low levels of CD4+ T cells (43).

The roles of DN T cells in tumor have been gradually unraveled. Young et al (44) demonstrated that isolated DN T cells are able to kill lymphoma A20 cells in vitro, and prevent lymphoma cell growth in a mouse model (44). Merims et al (45) proposed a novel approach to expand DN T cells isolated from leukemia patients in vitro, and the results indicated that expanded DN T cells were able to kill leukemia blast cells isolated from patients in vitro via a perforin-dependent mechanism (45). Additionally, Voelkl et al (46) identified a DN T cell clone capable of killing melanoma cell isolated from a patient.

The findings of the present study suggest that tumor cells might decrease the proportion of peripheral DN T cells by an unidentified mechanism in order to create a favorable peripheral environment for distant organ metastasis since DN T cells are able to kill tumor cells directly in the absence of CD8+ cells. If this finding is verified in future studies, DN T cells may be a promising therapeutic target for clinic prevention and control of metastasis. Further studies on the capability of DN T cells in the killing of NSCLC tumor cells would provide important insight.

Notably, the present study also observed that the proportion of peripheral B lymphocytes in the NSCLC group was significantly lower compared with the in control group (P<0.0001), which has not previously been reported in any type of tumor. Except for its common function of antigen presentation and antibody production or secretion, the role of B lymphocytes in tumor has long been observed (47–49). Many studies using murine models demonstrated that B cells were able to markedly suppress antitumor immunity in various types of tumor. In the B cell deficient mice (BCDM) model, slow growth or regression of implanted tumors was associated with indicators of antitumor immune responses, including dense infiltration of CD4+ and CD8+ T cells in the tumor bed, increased Th1 response and enhanced Cytotoxic T lymphocyte-mediated cytotoxity against tumor cells (48). By contrast, tumor growth restored when B cells were transplanted into BCDM or wild-type mice (48–50).

A subset of B cells was recognized with immunosuppressive function, namely B regulatory cells (Breg) (51). Breg has been identified with different phenotypes in different settings. Studies indicated that B regs were able to induce primary CD4+ T cell differentiation into the Th1/Th2 type (52). However, the mechanism and the specific conditions that enable B reg cells to exert this function are unclear. Moreover, B regs have been demonstrated to be able to promote the conversion of naive CD4+ T cells into Tregs, Tregs have been established to exert an important immunosuppressive role in TME. A number of studies support that the observation that the effect of Bregs in tumor may be mediated by the conversion of Tregs (53). In tumor models, Bregs have been observed to infiltrate tumor tissues. Tumor infiltrating Bregs [(TIL, tumor-infiltrating lymphocytes)-Bregs] are able to express various immunosuppressive molecules, which may mediate their immunosuppressive effect (53). However, the role of Bregs in tumor remains controversial since studies indicate that TIL-Breg is associated with improved survival (54), and some studies indicated that B cells may have a protective against tumor (55). Based on these studies, it is hypothesized that the preliminary findings of the present study indicate that B cells may be recruited into tumor tissues.

Circulating cytokine is closely associated with systemic and local immune status in disease, such as cancer. In the present study, it was observed that the level of IL-6 in the NSCLC group was significantly higher compared with the control group (P=0.008), whereas the proportions of the other 7 cytokines, including IFN-γ, TNF-α, TGF-β, IL-2, IL-4, IL-10 and IL-17A, were not significantly different between the NSCLC group and the control group. In addition, the levels of none of the cytokines was significantly different between subgroups I and II. Previous in vitro experiments demonstrated that IL-6 may have a dual role in antitumor immunity. IL-6 is able to promote tumor growth through downstream mediators and help sustain immunosuppressive milieu in TME (56). Additionally, IL-6 is also an important mediator of T cell recruitment to lymph nodes and tumor site, and skewing the conversion of CD4+ T cells from Tregs to a Th17 phenotype (56). Lippitz (57) also concluded that circulating IL-6 level is elevated in cancer patients and is also correlated with poor prognosis (50). Moreover, Lippitz (57) proposed that systemic cytokine cascade is characteristic of cancer (50).

The authors of the present study support the hypothesis that systemic cytokine changes are closely associated with tumor progression, which may be regulated by the tumor considering tumor cells are able to secret various pro-tumor cytokines. Although, in the present study, significant changes in the levels of cytokines were not observed, which is inconsistent with the analysis of Lippitz (57), the reason may be due to a relatively smaller sample size used in the present study. The present authors support the hypothesis that systemic cytokine cascade exists in patients with tumors, which reflects tumor stage and host immune status. Furthermore, these changes in the level of cytokines may be potential targets for immunotherapy.

In conclusion, it was observed in the present study that in NSCLC patients, the proportion of lymphocytes and two subpopulations (CD3+CD4-CD8- and CD19+) were significantly different between NSCLC patients and healthy controls.

The level of circulating IL-6 in NSCLC patients was also significantly higher in the NSCLC group compared with healthy controls. These preliminary results support the hypothesis that peripheral immune system is adapted by tumor lesion, and a further question is whether if it is a strategy adopted by tumor cells in order to facilitate progression and metastasis. Further studies which focus on the role of peripheral B cells and DN T cells in tumor may determine if these cells have a role in immunosurveillance and provide a novel strategy for immunotherapy.

 Acknowledgements

Not applicable.

 Funding

No funding was received.

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

HL analyzed the data and was a major contributor in writing the manuscript. XC made substantial contribution to the conception and design of study and gave the final approval of the version to be published. JZ had major role in designing the study. GX and YS made substantial contribution in analysis and interpretation of the data. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

This study was approved by Research Ethics Committee of the General Hospital of People's Liberation Army (approval no. S2015-02-11). All patients provided informed consent to participate this study.

 Consent for publication

Informed consent was obtained from all patients included in this study for publication of the associated data and the accompanying image.

 Competing interests

The authors declare that they have no competing interests.

 Abbreviations NSCLC

non-small cell lung cancer

 TME

tumor microenvironment

 MDSC

myeloid-derived suppressor cell

 Treg

regulatory T lymphocyte

 SCLC

small cell lung cancer

 IFN-γ

interferon-γ

 TNF-α

tumor necrosis factor-α

 TGF-β

transcription growth factor-β

 SD

standard deviation

 References GrossLIntradermal immunization of C3H mice against a sarcoma that originated in an animal of the same lineCancer Res33263331943 PrehnRTMainJMImmunity to methylcholanthrene-induced sarcomasJ Natl Cancer Inst18769778195713502695 HewittHBBlakeERWalderASA critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous originBr J Cancer33241259197610.1038/bjc.1976.37773395 KleinGKleinEImmune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: Contrasting consequences of host versus tumor evolutionProc Natl Acad Sci USA7421212125197710.1073/pnas.74.5.2121194247 SchreiberRDOldLJSmythMJCancer immunoediting: Integrating immunity's roles in cancer suppression and promotionScience33115651570201110.1126/science.120348621436444 ChenFZhuangXLinLYuPWangYShiYHuGSunYNew horizons in tumor microenvironment biology: Challenges and opportunitiesBMC Med1345201510.1186/s12916-015-0278-725857315 SwartzMAIidaNYullFERobertsEWSangalettiSWongMHYullFECoussensLMDeClerckYATumor microenvironment complexity: Emerging roles in cancer therapyCancer Res7224732480201210.1158/0008-5472.CAN-12-012222414581 LindauDGielenPKroesenMWesselingPAdemaGJThe immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cellsImmunology138105115201310.1111/imm.1203623216602 ObeidENandaRFuYXOlopadeOIThe role of tumor-associated macrophages in breast cancer progression (Review)Int J Oncol43512201310.3892/ijo.2013.193823673510 ShigaKHaraMNagasakiTSatoTTakahashiHTakeyamaHCancer-associated fibroblasts: Their characteristics and their roles in tumor growthCancer (Basel)724432458201510.3390/cancers7040902 AndersonACJollerNKuchrooVKLag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulationsImmunity449891004201610.1016/j.immuni.2016.05.00127192565 SmigielKSSrivastavaSStolleyJMCampbellDJRegulatory T-cell homeostasis: Steady-state maintenance and modulation during inflammationImmunol Rev2594045201410.1111/imr.1217024712458 OttPAHodiFSRobertCCTLA-4 and PD-1/PD-L1blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patientsClin Cancer Res1953005309201310.1158/1078-0432.CCR-13-014324089443 RomanoERomeroPThe therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: Unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumorsJ Immunother Cancer315201510.1186/s40425-015-0059-z25901287 MitchemJBBrennanDJKnolhoffBLBeltBAZhuYSanfordDEBelaygorodLCarpenterDCollinsLPiwnica-WormsDTargeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression and improves chemotherapeutics responsesCancer Res7311281141201310.1158/1538-7445.TUMIMM2012-B8323221383 McAllisterSSWeinbergRAThe tumour-induced systemic environment as a critical regulator of cancer progression and metastasisNat Cell Biol16717727201410.1038/ncb301525082194 HiratsukaSNakamuraKIwaiSMurakamiMItohTKijimaHShipleyJMSeniorRMShibuyaMMMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasisCancer Cell2289300200210.1016/S1535-6108(02)00153-812398893 KaplanRNRibaRDZacharoulisSBramleyAHVincentLCostaCMacDonaldDDJinDKShidoKKernsSAVEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic nicheNature438820827200510.1038/nature0418616341007 HiratsukaSWatanabeAAburataniHMaruYTumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasisNat Cell Biol813691375200610.1038/ncb150717128264 ErlerJTBennewithKLCoxTRLangGBirdDKoongALeQTGiacciaAJHypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic nicheCancer Cell153544200910.1016/j.ccr.2008.11.01219111879 KimSTakahashiHLinWWDescarguesPGrivennikovSKimYLuoJLKarinMCarcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasisNature457102106200910.1038/nature0762319122641 SceneayJChowMTChenAHalseHMWongCSAndrewsDMSloanEKParkerBSBowtellDDSmythMJMöllerAPrimary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic nicheCancer Res7239063911201210.1158/0008-5472.CAN-11-387322751463 KangSYHalvorsenOJGravdalKBhattacharyaNLeeJMLiuNWJohnstonBTJohnstonABHaukaasSAAamodtKProsaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1Proc Natl Acad Sci USA1061211512120200910.1073/pnas.090312010619581582 GranotZHenkeEComenEAKingTANortonLBenezraRTumor entrained neutrophils inhibit seeding in the premetastatic lungCancer Cell20300314201110.1016/j.ccr.2011.08.01221907922 TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin6587108201510.3322/caac.2126225651787 KurusuYYamashitaJOgawaMDetection of circulating tumor cells by reverse transcriptasepolymerase chain reaction in patients with resectable non-small-cell lung cancerSurgery126820826199910.1016/S0039-6060(99)70020-610568179 GrabenbauerGGLahmerGDistelLNiedobitekGTumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinomaClin Cancer Res1233553360200610.1158/1078-0432.CCR-05-243416740757 MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature480480489201110.1038/nature1067322193102 FriedlPAlexanderSCancer invasion and the microenvironment: Plasticity and reciprocityCell1479921009201110.1016/j.cell.2011.11.01622118458 PietrasKOstmanAHallmarks of cancer: Interactions with the tumor stromaExp Cell Res31613241331201010.1016/j.yexcr.2010.02.04520211171 CarliniMJDe LorenzoMSPuricelliLCross-talk between tumor cells and the microenvironment at the metastatic nicheCurr Pharm Biotechnol1219001908201110.2174/13892011179837705821470134 McAllisterSSGiffordAMGreinerALKelleherSPSaelzlerMPInceTAReinhardtFHarrisLNHylanderBLRepaskyEAWeinbergRASystemic endocrine instigation of indolent tumor growth requires osteopontinCell1339941005200810.1016/j.cell.2008.04.04518555776 CurielTJCoukosGZouLAlvarezXChengPMottramPEvdemon-HoganMConejo-GarciaJRZhangLBurowMSpecific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNat Med10942949201410.1038/nm1093 JóźwickiWBrożynaAASiekieraJSlominskiATFrequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removalOncotraget711450114622016 FogarPSpertiCBassoDSanzariMCGrecoEDavoliCNavagliaFZambonCFPasqualiCVenzaEDecreased total lymphocyte counts in pancreatic cancer: An index of adverse outcomePancreas322228200610.1097/01.mpa.0000188305.90290.5016340740 AhmadSSAkhtarKVermaAKMallikAZSiddiquiSATotal peripheral lymphocyte count in malignant tumors: An index of prognosticationJ Med Sci122428201210.3923/jms.2012.24.28 Ray-CoquardICropetCVan GlabbekeMSebbanCLe CesneAJudsonITredanOVerweijJBironPLabidiILymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomasCancer Res6953835391200910.1158/0008-5472.CAN-08-384519549917 FischerKVoelklSHeymannJPrzybylskiGKMondalKLaumerMKunz-SchughartLSchmidtCAAndreesenRMackensenAIsolation and characterization of human antigen-specific TCR alpha beta+ CD4 (-)CD8- double-negative regulatory T cellsBlood10528282835201510.1182/blood-2004-07-2583 ThomsonCWLeeBPZhangLDouble-negative regulatory T cells: Non-conventional regulatorsImmunol Res35163178200610.1385/IR:35:1:16317003518 PriatelJJUttingOTehHSTCR/self-antigen interactions drive double-negative T cell peripheral expansion and differentiation into suppressor cellsJ Immunol16761886194200110.4049/jimmunol.167.11.618811714779 VoelklSGaryRMackensenACharacterization of the immunoregulatory function of human TCR-αβ+ CD4-CD8- double-negative T cellsEur J Immunol41739748201110.1002/eji.20104098221287552 LigockiAJNiederkornJYAdvances on Non-CD4+Foxp3+T regulatory cells: CD8+, Type1, and double negative t regulatory cells in organ transplantationTransplantation9915531559201510.1097/TP.000000000000081326193065 SundaravaradanVMirKDSodoraDLDouble-negative T cells during HIV/SIV infections: Potential pinch hitters in the T cell lineupCurr Opin HIV AIDS7164171201210.1097/COH.0b013e3283504a6622241163 YoungKJKayLSPhillipsMJZhangLAntitumor activity mediated by double-negative T cellsCancer Res6380148021200314633734 MerimsSLiXJoeBDokouhakiPHanMChildsRWWangZYGuptaVMindenMDZhangLAnti-leukemia effect of ex vivo expanded DNT cells from AML patients: A potential novel autologous T-cell adoptive immunotherapyLeukemia2514151422201110.1038/leu.2011.9921566657 VoelklSMooreTVRehliMNishimuraMIMackensenAFischerKCharacterization of MHC class-I restricted TCR+ CD4-CD8-double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccinationCancer Immunol Immunother58709718200910.1007/s00262-008-0593-318836718 QinZRichterGSchülerTIbeSCaoXBlankensteinTB cells inhibit induction of T cell-dependent tumor immunityNat Med4627630199810.1038/nm0598-6279585241 ShahSDivekarAAHilcheySPChoHMNewmanCLShinSUNechustanHChallita-EidPMSegalBMYiKHRosenblattJDIncreased rejection of primary tumors in mice lacking B cells: Inhibition of antitumor CTL and TH1 cytokine responses by B cellsInt J Cancer117574586200510.1002/ijc.2117715912532 Lee-ChangCBodogaiMMartin-MontalvoAWejkszaKSanghviMMoaddelRde CaboRBiragynAInhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cellsJ Immunol19141414151201310.4049/jimmunol.130060624043896 ZhangYEliavYShinSUSchreiberTHPodackERTadmorTRosenblattJDB lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretionCancer Immunol Immunother628789201310.1007/s00262-012-1313-622772949 CunninghamRCAutoimmunity in primary immune deficiency: Taking lessons from our patientsClin Exp Immunol164Suppl 2S6S11201110.1111/j.1365-2249.2011.04388.x HarrisDPHaynesLSaylesPCDusoDKEatonSMLepakNMJohnsonLLSwainSLLundFEReciprocal regulation of polarized cytokine production by effector B and T cellsNat Immunol1475200010.1038/8271711101868 OlkhanudPBDamdinsurenBBodogaiMGressRESenRWejkszaKWerstoRPBiragynATumor evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cellsCancer Res7135053515201110.1158/0008-5472.CAN-10-431621444674 MilneKKöbelMKallogerSEBarnesROGaoDGilksCBWatsonPHNelsonBHSystematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factorsPLoS One4e6412200910.1371/journal.pone.000641219641607 KobayashiTHamaguchiYHasegawaMFujimotoMTakeharaKMatsushitaTB cells promote tumor immunity against B16F10 melanomaAm J Pathol18431203129201410.1016/j.ajpath.2014.07.00325173132 FisherDTAppenheimerMMEvansSSThe two faces of IL-6 in the tumor microenvironmentSemin Immunlo263847201410.1016/j.smim.2014.01.008 LippitzBECytokine patterns in patients with cancer: A systematic reviewLancet Oncol14e218e228201310.1016/S1470-2045(12)70582-X23639322

Distribution of lymphocyte subsets from peripheral blood as determined by flow cytometry. (A) Expression of CD19, and B lymphocyte is indicated as CD19+. (B) Co-expression of CD4 and CD8 by CD3+ lymphocyte. A distinct subset of CD4-CD8- is shown in the lower left quadrant. (C) Co-expression of CD4 and CD25 by CD3+ lymphocyte. The CD4+CD25+ subset in the upper left quadrant is indicated as activated CD4+ T lymphocyte, and a relatively distinct subset of CD4+CD25+ expressing high CD25 is identified as Treg. (D) Co-expression of CD3 and CD16+56, A subset of CD3+CD16+CD56+ in the upper right quadrant is indicated as NKT cells, A subset of CD3-CD16+CD56+ in the lower right quadrant is indicated as NK cells. CD, cluster of differentiation; FITC, fluorescein isothiocyanate; lym, lymphocyte; NK cells, natural killer cells; NKT, natural killer T lymphocytes; PC, phycoerythrin cyanin; PE, phycoerythrin; Treg, regulatory T lymphocyte.

Comparison of lymphocytes in the NSCLC group and the control group. The percentage of lymphocytes is significantly lower in the NSCLC group compared with the control group. P=0.008. NSCLC, non-small cell lung cancer.

Comparison of B lymphocytes in the NSCLC group and the control group. The proportion of peripheral B lymphocytes is significantly lower in the NSCLC group compared with the control group. P<0.0001. NSCLC, non-small cell lung cancer.

Comparison of CD3+CD4-CD8-T cells in the NSCLC group and the control group. The proportion of peripheral CD3+CD4-CD8-T cells is significantly lower in the NSCLC group compared with the control group. P=0.001. CD, cluster of differentiation; NSCLC, non-small cell lung cancer.

Comparison of lymphocytes in the NSCLC group and the control group. The percentage of lymphocytes in subgroup II (NSCLC with metastasis) is significantly lower compared with subgroup I (NSCLC without metastasis). P<0.0001. NSCLC, non-small cell lung cancer.

Basic information of participants.

NSCLC group Control group
Parameters Subgroup I Subgroup II CCWD LH CFD
Gender
  Male   8 22 14 1
  Female   9 9 4 2
Pathology
  Adenocarcinoma 12 17
  Squamous cell carcinoma   3 11
  Adenosquamous carcinoma   2 1
  Large-cell lung carcinoma   0 2
Metastasis
  N1-N2   0 14
  N3 or distant organ metastasis   0 17

CCWD, congenital chest wall deformity; LH, lung hamartoma; CFD, costal fibrous dysplasia; NSCLC, non-small cell lung cancer; N1, hilar or intralobal lymph node metastasis; N2, ipsolateral mediastinal lymph node metastasis; N3, contralateral hilar or mediastinal or supraclavicular lymph node metastasis.

Comparison of lymphocyte subsets between the NSCLC group and the control group.

Lymphocyte subsets NSCLC group (mean ± SD) Control group P-valuea
Lymphocyte 0.247±0.09 0.318±0.117 0.008
CD3+ 0.699±0.092 0.722±0.055 0.288
CD3+CD4+ 0.410±0.08 0.384±0.078 0.222
CD3+CD8+ 0.267±0.074 0.285±0.062 0.346
CD3+CD4−CD8− 0.032±0.018 0.054±0.034 0.001
CD3+CD4+CD25+ 0.094±0.053 0.103±0.033 0.076
CD3+CD4+CD25high 0.002±0.003 0.001±0.002 0.059
CD19+ 0.110±0.044 0.152±0.047 <0.0001
CD3+CD16+CD56+ 0.080±0.057 0.081±0.091 0.291
CD3−CD16+CD56+ 0.168±0.098 0.123±0.040 0.080
CD4+/CD8+ 1.681±0.639 1.449±0.572 0.159

Lymphocyte, percentage of lymphocytes; SD, standard deviation; CD3+CD4−CD8−, double negative T lymphocyte; CD19+, B lymphocytes; CD3+CD4+CD25high, regulatory T lymphocytes; CD3+CD16+CD56+, natural killer T cells; CD3−CD16+CD56+, natural killer cells.

NSCLC group vs. control group. CD, cluster of differentiation; NSCLC, non-small cell lung cancer.

Comparison of lymphocyte subsets between subgroups I and II.

Lymphocyte subsets Subgroup I Subgroup II P-valuea
Lymphocyte 0.309±0.094 0.214±0.066 <0.001
CD3+ 0.716±0.106 0.689±0.084 0.354
CD3+CD4+ 0.434±0.062 0.397±0.087 0.125
CD3+CD8+ 0.254±0.088 0.275±0.065 0.196
CD3+CD4−CD8− 0.034±0.019 0.030±0.019 0.360
CD3+CD4+CD25+ 0.086±0.025 0.098±0.025 0.875
CD3+CD4+CD25high 0.002±0.000 0.002±0.004 0.883
CD19+ 0.106±0.025 0.112±0.052 0.931
CD3+CD16+CD56+ 0.063±0.048 0.090±0.061 0.070
CD3−CD16+CD56+ 0.163±0.110 0.170±0.095 0.813
CD4+/CD8+ 1.889±0.590 1.567±0.644 0.059

Subgroup I vs. subgroup II. CD, cluster of differentiation.

Comparison of the levels of cytokines between the NSCLC group and control group

Cytokines NSCLC group (pg/ml) Control group (pg/ml) P-valuea
IL-2 1.07±0.827 1.40±0.426 0.083
IL-4 1.38±1.151 1.75±0.872 0.093
IL-6 6.01±3.292 3.86±2.184 0.008
IL-10 5.25±1.721 5.28±1.584 0.988
IL-17A 2.01±1.226 1.99±0.435 0.081
TNF-α 0.35±0.379 0.35±0.301 0.652
TGF-β 55,920±15,692 56,224±10,178 0.864
IFN-γ 3.57±2.050 3.83±2.404 0.675

NSCLC group vs. control group. IL, interleukin; TNF, tumor necrosis factor; TGF, transforming growth factor; IFN, interferon.